Pulse Biosciences, Inc

Pulse Biosciences, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Pulse Biosciences, Inc. has 70.80M shares outstanding.

As of June 30, 2026, Pulse Biosciences, Inc. maintains a current ratio of 9.63, meaning it holds 9.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. posted a negative return on equity (ROE) of -78.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -67.90, reflecting losses generated across the asset base. The company generates approximately 9,808.33 in revenue per employee across its workforce of 105.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.24 indicates how many times Pulse Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. generated 1.04M in revenue and converted that into -70.07M in net income, yielding earnings per share of -1.03. EBITDA reached -71.79M, while operating income came in at -72.69M.

As of June 30, 2026, Pulse Biosciences, Inc. holds 88.95M in cash and equivalents against 5.93M in total debt, resulting in a net debt position of -88.95M. Total book value stands at 87.09M, with working capital of 82.91M providing operational flexibility.

Pulse Biosciences, Inc. produced -53.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -253,837.00 in capital expenditures, free cash flow totaled -53.73M - equivalent to -0.79 per share.

Over the twelve months ended June 30, 2026, Pulse Biosciences, Inc. posted a gross margin of 0.25, reflecting its pricing power and cost economics. The operating margin of -7,007.76 and net profit margin of -6,755.78 provide insight into operational efficiency.